Skip to main content
Clinical Trials/ACTRN12623000155695
ACTRN12623000155695
Not Yet Recruiting
Phase 1

A pilot study to test the effects of a single microdose of ayahuasca alkaloids on blood pathology of neurotransmitters and inflammation marker levels, safety observations, and mood self-efficacy in healthy adults

Biochem Industries Pty Ltd0 sites5 target enrollmentFebruary 16, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Cognitive impairment
Sponsor
Biochem Industries Pty Ltd
Enrollment
5
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 16, 2023
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Biochem Industries Pty Ltd

Eligibility Criteria

Inclusion Criteria

  • Participant is willing and able to give informed consent for participation in the trial
  • Adults aged 25\-60 years inclusive

Exclusion Criteria

  • Current use of any prescribed psychotropic medication
  • Significant renal or hepatic impairment as judged by study clinicians
  • Cardiovascular conditions including, abnormal heart rate or blood pressure to be checked at screening. A threshold of exceeding 160 mmHg (systolic) and 90 mmHg (diastolic), averaged across four assessments taken on the screening day will be used
  • Any unstable medical or neurologic condition
  • Current or past history diagnosis of schizophrenia or other psychotic disorders, or Bipolar I or II Disorder
  • Imminent risk of suicide
  • Lifetime presence of diagnosis of Major Depressive Disorder not in remission
  • Current diagnosis of panic disorders, OCD, dysthymic disorder, anorexia, or bulimia
  • Body\-weight \<50 kg or \>120 kg
  • Substance dependence diagnosis in the previous three months

Outcomes

Primary Outcomes

Not specified

Similar Trials